T-Ray Science, Inc.

T-Ray Science, Inc.

September 30, 2010 10:00 ET

T-Ray Science, Inc. Profiled on CTV News

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 30, 2010) - T-Ray Science, Inc. (TSX VENTURE:THZ) (the "Company" or "T-Ray") announces the technology behind the skin cancer detector the Company is in the process of commercializing was recently profiled by Dr. Rhonda Low of CTV News.

This device will greatly aid doctors in assessing skin lesions, providing more thorough care for their patients, and reducing mistakes due to human error. The tool can elevate the diagnostic capability of a primary care physician, thereby reducing patient wait times and helping to automate the process of the diagnosis of skin cancer. The technology is vitally important because while there fewer than 650 dermatologists in Canada, 1 in 7 (or approximately 5 million) Canadians will get skin cancer at some point during their lives.

Patients who are diagnosed with skin cancer in the early stage have a survival rate of 99% as opposed to only 15% if diagnosed at a late stage, and the treatment of advanced lesions is 2200% more expensive than that of early stage lesions. 

T-Ray's revolutionary device will increase the standard of care for patients and decrease healthcare costs by enabling early diagnosis. In addition to reducing wait times, the device will also assist doctors in determining the most dangerous lesions requiring biopsy, eliminating the unnecessary biopsies of innocent lesions.

Featured in the CTV News segment are Dr. Harvey Lui, the Head of the Department of Dermatology at UBC; and Dr. Haishan Zeng, a senior scientist with the BC Cancer Agency and Associate Professor of Dermatology and Skin Sciences at UBC. Both doctors, along with Dr. David McLean, Professor of Medicine, Department of Dermatology at UBC and former President of the Canadian Association of Dermatologists, are inventors of the technology used in T-Ray's skin cancer detector, and continue to be involved in building the prototype devices for clinical trials and obtaining approvals for the manufacturing and marketing of the device.

To view the complete video, click on the following link:


About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company committed to developing innovative systems for the early detection of cancer.

The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements.

This platform technology is also fully extensible to early detection systems for other types of cancer, including gastro-intestinal, colorectal and cervical cancers.

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information